|
Index | - | P/E | - | EPS (ttm) | -1.46 | Insider Own | 2.45% | Shs Outstand | 129.12M | Perf Week | 1.70% |
Market Cap | 639.85M | Forward P/E | - | EPS next Y | -1.91 | Insider Trans | 0.00% | Shs Float | 126.13M | Perf Month | -39.72% |
Income | -187.80M | PEG | - | EPS next Q | -0.41 | Inst Own | 91.80% | Short Float | 7.03% | Perf Quarter | -56.66% |
Sales | - | P/S | - | EPS this Y | -393.20% | Inst Trans | 1.61% | Short Ratio | 14.23 | Perf Half Y | -70.69% |
Book/sh | 3.94 | P/B | 1.21 | EPS next Y | -21.20% | ROA | -30.10% | Target Price | 24.75 | Perf Year | -75.09% |
Cash/sh | 2.84 | P/C | 1.69 | EPS next 5Y | - | ROE | -32.60% | 52W Range | 3.90 - 23.68 | Perf YTD | -72.06% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -79.81% | Beta | - |
Dividend % | - | Quick Ratio | 10.60 | Sales past 5Y | - | Gross Margin | - | 52W Low | 22.56% | ATR | 0.62 |
Employees | 412 | Current Ratio | 10.60 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 37.61 | Volatility | 9.96% 13.71% |
Optionable | Yes | Debt/Eq | 0.00 | EPS Q/Q | -133.30% | Profit Margin | - | Rel Volume | 1.11 | Prev Close | 4.83 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 622.84K | Price | 4.78 |
Recom | 1.70 | SMA20 | -11.22% | SMA50 | -28.42% | SMA200 | -64.43% | Volume | 688,083 | Change | -1.04% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas. | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite